AHA summary of Pfizer COVID-19 vaccine EUA
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
The summary covers dosing, storage and handling, preparation, and contraindications and adverse reactions. View the AHA Special Bulletin and review AHA resources on this and other COVID-19 vaccines and treatments.
Also over the weekend, the Centers for Disease Control and Prevention formally recommended the vaccine’s use for patients age 16 and older
Related News Articles
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…